Analysis of Multiple Endpoints in Clinical Trials
Most human diseases are characterized by multidimensional etiology and the efficacy of an experimental treatment frequently needs to be assessed on multiple outcome measures — commonly referred to as endpoints. There is a variety of ways in which the contribution of each endpoint can be accounted for...
Gespeichert in:
| Format: | Buchkapitel |
|---|---|
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 182 |
|---|---|
| container_issue | |
| container_start_page | 149 |
| container_title | |
| container_volume | |
| description | Most human diseases are characterized by multidimensional etiology and
the efficacy of an experimental treatment frequently needs to be assessed on
multiple outcome measures — commonly referred to as endpoints. There is a
variety of ways in which the contribution of each endpoint can be accounted
for in the primary analysis, for example, the trial’s sponsor can treat endpoints
as independent entities or as manifestations of a single underlying cause. The
following examples illustrate the common approaches to analyzing multiple
endpoints. |
| doi_str_mv | 10.1201/9781584889854-9 |
| format | Book Chapter |
| fullrecord | <record><control><sourceid>proquest_infor</sourceid><recordid>TN_cdi_proquest_ebookcentralchapters_599708_10_150</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>EBC599708_10_150</sourcerecordid><originalsourceid>FETCH-LOGICAL-i303t-98a954206c294be6770ed8ca7c5a734336424b55c3493440c9a22621e72475253</originalsourceid><addsrcrecordid>eNpVkE1LAzEYhCOiWGvPXvcPrOb741hKrULFSz2HbJrFaEzWJFX6712tiM5lGN53nsMAcIngFcIQXSshEZNUSiUZbdUROP-N5BjM_pypOAUTzolSCiJ-BmalPMNRFBMO5QSgeTRhX3xpUt_c70L1Q3DNMm6H5GMtjY_NIvjorQnNJnsTygU46Udzsx-fgseb5WZx264fVneL-br1BJLaKmkUoxhyixXtHBcCuq20RlhmBKGEcIppx5glVBFKoVUGY46RE5gKhhmZAnzgDjm97Vyp2nUpvVgXazbBPpmhulw0U0pAqRHUiMGxtDqUfOxTfjUfKYetrmYfUu6zidaXL0j5_h-X1P-W1Eq_j0yfIiafdBRlgw</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>book_chapter</recordtype><pqid>EBC599708_10_150</pqid></control><display><type>book_chapter</type><title>Analysis of Multiple Endpoints in Clinical Trials</title><source>eBooks on EBSCOhost</source><contributor>Bretz, Frank ; Dmitrienko, Alex ; Tamhane, Ajit C. ; Tamhane, Ajit C ; Dmitrienko, Alex ; Bretz, Frank</contributor><creatorcontrib>Bretz, Frank ; Dmitrienko, Alex ; Tamhane, Ajit C. ; Tamhane, Ajit C ; Dmitrienko, Alex ; Bretz, Frank</creatorcontrib><description>Most human diseases are characterized by multidimensional etiology and
the efficacy of an experimental treatment frequently needs to be assessed on
multiple outcome measures — commonly referred to as endpoints. There is a
variety of ways in which the contribution of each endpoint can be accounted
for in the primary analysis, for example, the trial’s sponsor can treat endpoints
as independent entities or as manifestations of a single underlying cause. The
following examples illustrate the common approaches to analyzing multiple
endpoints.</description><identifier>ISBN: 9781584889847</identifier><identifier>ISBN: 1584889845</identifier><identifier>EISBN: 1584889853</identifier><identifier>EISBN: 9781584889854</identifier><identifier>EISBN: 0429191863</identifier><identifier>EISBN: 9780429191862</identifier><identifier>DOI: 10.1201/9781584889854-9</identifier><identifier>OCLC: 663999016</identifier><identifier>LCCallNum: RM301.27 .M85 2010</identifier><language>eng</language><publisher>United Kingdom: Chapman and Hall/CRC</publisher><subject>Clinical trials ; Epidemiology & medical statistics ; Pharmacology</subject><ispartof>Multiple Testing Problems in Pharmaceutical Statistics, 2010, p.149-182</ispartof><rights>2010 by Taylor and Francis Group, LLC Chapman & Hall/CRC is an imprint of Taylor & Francis Group, an Informa business No claim to original U.S. Government works</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttps://ebookcentral.proquest.com/covers/599708-l.jpg</thumbnail><link.rule.ids>779,780,784,793,27924</link.rule.ids></links><search><contributor>Bretz, Frank</contributor><contributor>Dmitrienko, Alex</contributor><contributor>Tamhane, Ajit C.</contributor><contributor>Tamhane, Ajit C</contributor><contributor>Dmitrienko, Alex</contributor><contributor>Bretz, Frank</contributor><title>Analysis of Multiple Endpoints in Clinical Trials</title><title>Multiple Testing Problems in Pharmaceutical Statistics</title><description>Most human diseases are characterized by multidimensional etiology and
the efficacy of an experimental treatment frequently needs to be assessed on
multiple outcome measures — commonly referred to as endpoints. There is a
variety of ways in which the contribution of each endpoint can be accounted
for in the primary analysis, for example, the trial’s sponsor can treat endpoints
as independent entities or as manifestations of a single underlying cause. The
following examples illustrate the common approaches to analyzing multiple
endpoints.</description><subject>Clinical trials</subject><subject>Epidemiology & medical statistics</subject><subject>Pharmacology</subject><isbn>9781584889847</isbn><isbn>1584889845</isbn><isbn>1584889853</isbn><isbn>9781584889854</isbn><isbn>0429191863</isbn><isbn>9780429191862</isbn><fulltext>true</fulltext><rsrctype>book_chapter</rsrctype><creationdate>2010</creationdate><recordtype>book_chapter</recordtype><recordid>eNpVkE1LAzEYhCOiWGvPXvcPrOb741hKrULFSz2HbJrFaEzWJFX6712tiM5lGN53nsMAcIngFcIQXSshEZNUSiUZbdUROP-N5BjM_pypOAUTzolSCiJ-BmalPMNRFBMO5QSgeTRhX3xpUt_c70L1Q3DNMm6H5GMtjY_NIvjorQnNJnsTygU46Udzsx-fgseb5WZx264fVneL-br1BJLaKmkUoxhyixXtHBcCuq20RlhmBKGEcIppx5glVBFKoVUGY46RE5gKhhmZAnzgDjm97Vyp2nUpvVgXazbBPpmhulw0U0pAqRHUiMGxtDqUfOxTfjUfKYetrmYfUu6zidaXL0j5_h-X1P-W1Eq_j0yfIiafdBRlgw</recordid><startdate>2010</startdate><enddate>2010</enddate><general>Chapman and Hall/CRC</general><general>Taylor & Francis Group</general><scope>FFUUA</scope></search><sort><creationdate>2010</creationdate><title>Analysis of Multiple Endpoints in Clinical Trials</title></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-i303t-98a954206c294be6770ed8ca7c5a734336424b55c3493440c9a22621e72475253</frbrgroupid><rsrctype>book_chapters</rsrctype><prefilter>book_chapters</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Clinical trials</topic><topic>Epidemiology & medical statistics</topic><topic>Pharmacology</topic><toplevel>online_resources</toplevel><collection>ProQuest Ebook Central - Book Chapters - Demo use only</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bretz, Frank</au><au>Dmitrienko, Alex</au><au>Tamhane, Ajit C.</au><au>Tamhane, Ajit C</au><au>Dmitrienko, Alex</au><au>Bretz, Frank</au><format>book</format><genre>bookitem</genre><ristype>CHAP</ristype><atitle>Analysis of Multiple Endpoints in Clinical Trials</atitle><btitle>Multiple Testing Problems in Pharmaceutical Statistics</btitle><date>2010</date><risdate>2010</risdate><spage>149</spage><epage>182</epage><pages>149-182</pages><isbn>9781584889847</isbn><isbn>1584889845</isbn><eisbn>1584889853</eisbn><eisbn>9781584889854</eisbn><eisbn>0429191863</eisbn><eisbn>9780429191862</eisbn><abstract>Most human diseases are characterized by multidimensional etiology and
the efficacy of an experimental treatment frequently needs to be assessed on
multiple outcome measures — commonly referred to as endpoints. There is a
variety of ways in which the contribution of each endpoint can be accounted
for in the primary analysis, for example, the trial’s sponsor can treat endpoints
as independent entities or as manifestations of a single underlying cause. The
following examples illustrate the common approaches to analyzing multiple
endpoints.</abstract><cop>United Kingdom</cop><pub>Chapman and Hall/CRC</pub><doi>10.1201/9781584889854-9</doi><oclcid>663999016</oclcid><tpages>34</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISBN: 9781584889847 |
| ispartof | Multiple Testing Problems in Pharmaceutical Statistics, 2010, p.149-182 |
| issn | |
| language | eng |
| recordid | cdi_proquest_ebookcentralchapters_599708_10_150 |
| source | eBooks on EBSCOhost |
| subjects | Clinical trials Epidemiology & medical statistics Pharmacology |
| title | Analysis of Multiple Endpoints in Clinical Trials |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T16%3A07%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_infor&rft_val_fmt=info:ofi/fmt:kev:mtx:book&rft.genre=bookitem&rft.atitle=Analysis%20of%20Multiple%20Endpoints%20in%20Clinical%20Trials&rft.btitle=Multiple%20Testing%20Problems%20in%20Pharmaceutical%20Statistics&rft.au=Bretz,%20Frank&rft.date=2010&rft.spage=149&rft.epage=182&rft.pages=149-182&rft.isbn=9781584889847&rft.isbn_list=1584889845&rft_id=info:doi/10.1201/9781584889854-9&rft_dat=%3Cproquest_infor%3EEBC599708_10_150%3C/proquest_infor%3E%3Curl%3E%3C/url%3E&rft.eisbn=1584889853&rft.eisbn_list=9781584889854&rft.eisbn_list=0429191863&rft.eisbn_list=9780429191862&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=EBC599708_10_150&rft_id=info:pmid/&rfr_iscdi=true |